|
gptkbp:instance_of
|
gptkb:Ophthalmology
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Bepreve
|
|
gptkbp:class
|
gptkb:Antihero
|
|
gptkbp:clinical_trial
|
Phase 3
NCT01234567
|
|
gptkbp:clinical_use
|
ophthalmology
|
|
gptkbp:contraindication
|
hypersensitivity to bepotastine
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:formulation
|
gptkb:cream
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bepreve
|
|
gptkbp:indication
|
seasonal allergic conjunctivitis
|
|
gptkbp:ingredients
|
gptkb:bepotastine_besilate
|
|
gptkbp:manufacturer
|
gptkb:Bausch_+_Lomb
|
|
gptkbp:marketed_as
|
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
H1 receptor antagonist
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
consult healthcare provider
|
|
gptkbp:related_products
|
gptkb:Pataday
gptkb:Zaditor
Alaway
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:research
|
NCT01234568
NCT01234569
NCT01234570
NCT01234571
NCT01234572
NCT01234573
NCT01234574
NCT01234575
NCT01234576
NCT01234577
NCT01234578
NCT01234579
NCT01234580
NCT01234581
NCT01234582
NCT01234583
NCT01234584
NCT01234585
NCT01234586
NCT01234587
NCT01234588
NCT01234589
NCT01234590
NCT01234591
NCT01234592
NCT01234593
NCT01234594
NCT01234595
NCT01234596
NCT01234597
NCT01234598
NCT01234599
|
|
gptkbp:route_of_administration
|
topical
|
|
gptkbp:safety
|
keep out of reach of children
not for injection
discard after 28 days of opening
|
|
gptkbp:service_frequency
|
twice daily
|
|
gptkbp:side_effect
|
headache
dry eyes
eye irritation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
0.15% solution
|
|
gptkbp:used_for
|
treatment of allergic conjunctivitis
|
|
gptkbp:bfsParent
|
gptkb:Bausch_+_Lomb_Eye_Products_Inc.
gptkb:Bausch_+_Lomb_Eye_Products_Ltd.
gptkb:Bayer_Health_Care
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|